US and Europe Pharma and Biotech Cro Market Research Report - Forecast to 2032

Table of Content

1 EXECUTIVE SUMMARY 19
2 MARKET INTRODUCTION 21
2.1 DEFINITION 21
2.2 SCOPE OF THE STUDY 21
2.3 RESEARCH OBJECTIVE 21
2.4 MARKET STRUCTURE 21
3 RESEARCH METHODOLOGY 22
3.1 OVERVIEW 22
3.2 DATA FLOW 24
3.2.1 DATA MINING PROCESS 24
3.3 PURCHASED DATABASE: 25
3.4 SECONDARY SOURCES: 26
3.4.1 SECONDARY RESEARCH DATA FLOW: 27
3.5 PRIMARY RESEARCH: 28
3.5.1 PRIMARY RESEARCH DATA FLOW: 29
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 30
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 31
3.6.1 REVENUE ANALYSIS APPROACH 31
3.7 DATA FORECASTING 32
3.7.1 DATA FORECASTING TYPE 32
3.8 DATA MODELING 33
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 33
3.8.2 DATA MODELING: 34
3.9 TEAMS AND ANALYST CONTRIBUTION 36
4 MARKET DYNAMICS 38
4.1 INTRODUCTION 38
4.2 DRIVERS 39
4.2.1 INCREASING RESEARCH AND DEVELOPMENT INVESTMENTS BY PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES 39
4.2.2 GROWING ADOPTION OF CUTTING-EDGE TECHNOLOGY SUCH AS ARTIFICIAL INTELLIGENCE, BIG DATA ANALYTICS, AND PRECISION MEDICINE 39
4.2.3 INCREASED NUMBER OF CLINICAL TRIALS AND STUDIES GENERATES DEMAND FOR CRO SERVICES FOR TRIAL MANAGEMENT AND SUPPORT 40
4.3 RESTRAINTS 41
4.3.1 HIGH COST OF PHOTODYNAMIC THERAPY EQUIPMENT AND PROCEDURES 41
4.4 OPPORTUNITY 42
4.4.1 GROWING INVESTMENT IN PERSONALIZED AND PRECISION MEDICINE 42
5 MARKET FACTOR ANALYSIS 44
5.1 PORTER’S FIVE FORCES MODEL 44
5.1.1 THREAT OF NEW ENTRANTS 44
5.1.2 BARGAINING POWER OF SUPPLIERS 45
5.1.3 THREAT OF SUBSTITUTES 45
5.1.4 BARGAINING POWER OF BUYERS 45
5.1.5 INTENSITY OF RIVALRY 45
5.2 IMPACT OF COVID-19 ON THE US & EUROPE PHARMA AND BIOTECH CRO MARKET 46
5.3 LIST OF CONTRACT RESEARCH ORGANIZATION BY EUROPE/EUROPE COUNTRIES OFFERING SERVICES TO PHARMACEUTICAL AND BIOPHARMACEUTICAL 47
6 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE 53
6.1 OVERVIEW 53
6.2 CLINICAL DEVELOPMENT SERVICES 56
6.3 FORMULATION DEVELOPMENT SERVICES 56
6.4 PHARMACOVIGILANCE SERVICES 56
6.5 LABORATORY SERVICES 57
6.6 CONSULTING SERVICES 57
6.7 DATA MANAGEMENT SERVICES 58
6.8 OTHERS 58
7 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY PHASE 59
7.1 OVERVIEW 59
7.2 PHASE I 62
7.3 PHASE II 62
7.4 PHASE III 62
7.5 PHASE IV 63
7.6 POST MARKETING STUDIES (PMS) 63
8 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY INDICATION 64
8.1 OVERVIEW 64
8.2 CARDIOVASCULAR 67
8.3 ONCOLOGY 67
8.4 DERMATOLOGY 67
8.5 GYNAECOLOGY 68
8.6 NEUROLOGY 68
8.7 RESPIRATORY DISEASES 68
8.8 ORTHOPAEDICS 69
8.9 OPHTHALMOLOGY 69
8.10 OTHERS 69
9 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY END USER 70
9.1 OVERVIEW 70
9.2 PHARMACEUTICAL COMPANIES 72
9.3 BIOPHARMACEUTICAL COMPANIES 72
10 US & EUROPE PHARMA AND BIOTECH CRO MARKET, BY REGION 73
10.1 OVERVIEW 73
10.2 US 75
10.3 EUROPE 78
10.4 EASTERN EUROPE 82
10.4.1 POLAND 86
10.4.2 ROMANIA 88
10.4.3 BULGARIA 90
10.4.4 BELARUS 92
10.4.5 GEORGIA 94
10.4.6 LATVIA 96
10.4.7 LITHUANIA 98
10.4.8 REST OF EASTERN EUROPE 100
10.5 WESTERN EUROPE 102
10.5.1 GERMANY 105
10.5.2 FRANCE 107
10.5.3 UK 109
10.5.4 SPAIN 111
10.5.5 SWITZERLAND 113
10.5.6 NETHERLANDS 115
10.5.7 REST OF WESTERN EUROPE 117
10.6 NORTHERN EUROPE 120
10.6.1 DENMARK 123
10.6.2 SWEDEN 125
10.6.3 NORWAY 127
10.6.4 ICELAND 129
10.6.5 FINLAND 131
10.6.6 IRELAND 133
10.6.7 REST OF NORTHERN EUROPE 135
10.7 SOUTHERN EUROPE 138
10.7.1 GREECE 141
10.7.2 PORTUGAL 143
10.7.3 CROATIA 145
10.7.4 REST OF SOUTHERN EUROPE 147
10.8 CENTRAL EUROPE 149
10.8.1 HUNGARY 153
10.8.2 SLOVAKIA 155
10.8.3 CZECH REPUBLIC 157
10.8.4 AUSTRIA 159
10.8.5 REST OF CENTRAL EUROPE 161
11 COMPETITIVE LANDSCAPE 164
11.1 INTRODUCTION 164
11.2 MARKET SHARE ANALYSIS, 2023 164
11.3 COMPETITOR DASHBOARD 165
11.4 PUBLIC PLAYERS STOCK SUMMARY 166
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 166
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 166
11.6.1 AQUISITION 166
11.6.2 FACILITY LAUNCH 168
11.6.3 INVESTMENT 168
11.6.4 EXPANSION 168
12 COMPANY PROFILES 169
12.1 KLIFO 169
12.1.1 COMPANY OVERVIEW 169
12.1.2 FINANCIAL OVERVIEW 169
12.1.3 SERVICE OFFERED 170
12.1.4 KEY DEVELOPMENTS 171
12.1.5 KEY STRATEGIES 171
12.2 OPTIMAPHARM 172
12.2.1 COMPANY OVERVIEW 172
12.2.2 FINANCIAL OVERVIEW 172
12.2.3 SERVICES OFFERED 173
12.2.4 KEY DEVELOPMENTS 174
12.2.5 SWOT ANALYSIS 175
12.2.6 KEY STRATEGIES 175
12.3 FGK CLINICAL RESEARCH GMBH 176
12.3.1 COMPANY OVERVIEW 176
12.3.2 FINANCIAL OVERVIEW 176
12.3.3 SERVICE OFFERED 177
12.3.4 KEY DEVELOPMENTS 178
12.3.5 KEY STRATEGIES 178
12.4 ERGOMED GROUP 179
12.4.1 COMPANY OVERVIEW 179
12.4.2 FINANCIAL OVERVIEW 180
12.4.3 SERVICE OFFERED 180
12.4.4 KEY DEVELOPMENTS 181
12.4.5 SWOT ANALYSIS 182
12.4.6 KEY STRATEGIES 182
12.5 ASTRUM/ PHARMALOG 183
12.5.1 COMPANY OVERVIEW 183
12.5.2 FINANCIAL OVERVIEW 183
12.5.3 SERVICE OFFERED 184
12.5.4 KEY DEVELOPMENTS 184
12.5.5 KEY STRATEGIES 184
12.6 KAPADI 185
12.6.1 COMPANY OVERVIEW 185
12.6.2 FINANCIAL OVERVIEW 186
12.6.3 SERVICES OFFERED 186
12.6.4 KEY DEVELOPMENTS 186
12.6.5 SWOT ANALYSIS 187
12.6.6 KEY STRATEGIES 187
12.7 TFS HEALTHSCIENCE 188
12.7.1 COMPANY OVERVIEW 188
12.7.2 FINANCIAL OVERVIEW 188
12.7.3 SERVICES OFFERED 189
12.7.4 KEY DEVELOPMENTS 189
12.7.5 KEY STRATEGIES 189
12.8 WINICKER NORIMED GMBH 190
12.8.1 COMPANY OVERVIEW 190
12.8.2 FINANCIAL OVERVIEW 190
12.8.3 SERVICES OFFERED 190
12.8.4 KEY DEVELOPMENTS 191
12.8.5 SWOT ANALYSIS 191
12.8.6 KEY STRATEGIES 191
12.9 JSB SOLUTIONS SRL 192
12.9.1 COMPANY OVERVIEW 192
12.9.2 FINANCIAL OVERVIEW 192
12.9.3 SERVICES OFFERED 193
12.9.4 KEY DEVELOPMENTS 193
12.9.5 KEY STRATEGIES 193
12.10 IQVIA HOLDING, INC 194
12.10.1 COMPANY OVERVIEW 194
12.10.2 FINANCIAL OVERVIEW 195
12.10.3 SERVICES OFFERED 195
12.10.4 KEY DEVELOPMENTS 196
12.10.5 SWOT ANALYSIS 196
12.10.6 KEY STRATEGIES 196
13 DATA CITATIONS 197
 

List of Figures

LIST OF FIGURES
FIGURE 1 US AND EUROPE PHARMA AND BIOTECH CRO MARKET: STRUCTURE 21
FIGURE 2 US & EUROPE PHARMA AND BIOTECH CRO MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032) 38
FIGURE 3 DRIVER IMPACT ANALYSIS (2019-2032) 40
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2029-2032) 42
FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: US & EUROPE PHARMA AND BIOTECH CRO MARKET 44
FIGURE 6 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, SERVICE TYPE, 2023 & 2032 (USD MILLION) 53
FIGURE 7 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2023 & 2032 (USD MILLION) 54
FIGURE 8 US AND EUROPE PHARMA AND BIOTECH CRO MARKET SHARE (%), BY SERVICE TYPE, 2023 55
FIGURE 9 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, PHASE, 2023 & 2032 (USD MILLION) 59
FIGURE 10 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2023 & 2032 (USD MILLION) 60
FIGURE 11 US AND EUROPE PHARMA AND BIOTECH CRO MARKET SHARE (%), BY PHASE, 2023 61
FIGURE 12 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, INDICATION, 2023 & 2032 (USD MILLION) 64
FIGURE 13 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2023 & 2032 (USD MILLION) 65
FIGURE 14 US AND EUROPE PHARMA AND BIOTECH CRO MARKET SHARE (%), BY INDICATION, 2023 66
FIGURE 15 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, END USER, 2023 & 2032 (USD MILLION) 70
FIGURE 16 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY END USER, 2023 & 2032 (USD MILLION) 71
FIGURE 17 US AND EUROPE PHARMA AND BIOTECH CRO MARKET SHARE (%), BY END USER, 2023 71
FIGURE 18 US & EUROPE PHARMA AND BIOTECH CRO MARKET, BY REGION, 2023 & 2032 (USD MILLION) 73
FIGURE 19 US & EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY REGION, 2023 (% SHARE) 74
FIGURE 20 US MARKET ANALYSIS: PHARMA AND BIOTECH CRO MARKET, 2019-2032 (USD MILLION) 75
FIGURE 21 EUROPE MARKET ANALYSIS: PHARMA AND BIOTECH CRO MARKET, 2019-2032 (USD MILLION) 78
FIGURE 22 EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY REGION, 2023 & 2032 (USD MILLION) 79
FIGURE 23 EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY REGION, 2023 (%) 80
FIGURE 24 EASTERN EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 82
FIGURE 25 EASTERN EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY REGION, 2023 (%) 83
FIGURE 26 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 102
FIGURE 27 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 (%) 103
FIGURE 28 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 120
FIGURE 29 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 (%) 121
FIGURE 30 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 138
FIGURE 31 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 (%) 139
FIGURE 32 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 149
FIGURE 33 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 (%) 150
FIGURE 34 US AND EUROPE PHARMA AND BIOTECH CRO MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 164
FIGURE 35 COMPETITOR DASHBOARD: US AND EUROPE PHARMA AND BIOTECH CRO MARKET 165
FIGURE 36 OPTIMAPHARM: SWOT ANALYSIS 175
FIGURE 37 ERGOMED GROUP: SWOT ANALYSIS 182
FIGURE 38 KAPADI: SWOT ANALYSIS 187
FIGURE 39 WINICKER NORIMED GMBH: SWOT ANALYSIS 191
FIGURE 40 IQVIA HOLDING, INC: SWOT ANALYSIS 195
FIGURE 41 IQVIA HOLDING, INC: SWOT ANALYSIS 196

List of Tables

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 34
TABLE 2 LIST OF CONTRACT RESEARCH ORGANIZATION BY EUROPE/EUROPE COUNTRIES OFFERING SERVICES TO PHARMACEUTICAL AND BIOPHARMACEUTICAL 47
TABLE 3 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 54
TABLE 4 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR CLINICAL DEVELOPMENT SERVICES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 56
TABLE 5 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR FORMULATION DEVELOPMENT SERVICES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 56
TABLE 6 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHARMACOVIGILANCE SERVICES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 56
TABLE 7 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR LABORATORY SERVICES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 57
TABLE 8 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR CONSULTING SERVICES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 57
TABLE 9 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR DATA MANAGEMENT SERVICES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 58
TABLE 10 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR OTHERS, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 58
TABLE 11 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 60
TABLE 12 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHASE I, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 62
TABLE 13 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHASE II, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 62
TABLE 14 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHASE III, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 62
TABLE 15 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHASE IV, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 63
TABLE 16 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR POST MARKETING STUDIES (PMS), BY COUNTRY/REGION, 2019–2032 (USD MILLION) 63
TABLE 17 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 65
TABLE 18 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR CARDIOVASCULAR, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 67
TABLE 19 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR ONCOLOGY, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 67
TABLE 20 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR DERMATOLOGY, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 67
TABLE 21 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR GYNAECOLOGY, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 68
TABLE 22 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR NEUROLOGY, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 68
TABLE 23 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 68
TABLE 24 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR ORTHOPAEDICS, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 69
TABLE 25 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR OPHTHALMOLOGY, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 69
TABLE 26 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR OTHERS, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 69
TABLE 27 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 71
TABLE 28 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 72
TABLE 29 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR BIOPHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 72
TABLE 30 US & EUROPE PHARMA AND BIOTECH CRO MARKET, BY REGION, 2019–2032 (USD MILLION) 73
TABLE 31 US: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 76
TABLE 32 US: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 76
TABLE 33 US: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 77
TABLE 34 US: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 77
TABLE 35 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY REGION, 2019–2032 (USD MILLION) 79
TABLE 36 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 80
TABLE 37 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 81
TABLE 38 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 81
TABLE 39 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 82
TABLE 40 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY REGION, 2019–2032 (USD MILLION) 83
TABLE 41 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 84
TABLE 42 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 84
TABLE 43 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 85
TABLE 44 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 85
TABLE 45 POLAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 86
TABLE 46 POLAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 86
TABLE 47 POLAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 87
TABLE 48 POLAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 87
TABLE 49 ROMANIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 88
TABLE 50 ROMANIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 88
TABLE 51 ROMANIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 89
TABLE 52 ROMANIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 89
TABLE 53 BULGARIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 90
TABLE 54 BULGARIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 90
TABLE 55 BULGARIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 91
TABLE 56 BULGARIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 91
TABLE 57 BELARUS: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 92
TABLE 58 BELARUS: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 92
TABLE 59 BELARUS: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 93
TABLE 60 BELARUS: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 93
TABLE 61 GEORGIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 94
TABLE 62 GEORGIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 94
TABLE 63 GEORGIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 95
TABLE 64 GEORGIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 95
TABLE 65 LATVIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 96
TABLE 66 LATVIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 96
TABLE 67 LATVIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 97
TABLE 68 LATVIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 97
TABLE 69 LITHUANIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 98
TABLE 70 LITHUANIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 98
TABLE 71 LITHUANIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 99
TABLE 72 LITHUANIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 99
TABLE 73 REST OF EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 100
TABLE 74 REST OF EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 100
TABLE 75 REST OF EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 101
TABLE 76 REST OF EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 101
TABLE 77 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 102
TABLE 78 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 103
TABLE 79 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 104
TABLE 80 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 104
TABLE 81 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 105
TABLE 82 GERMANY: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 105
TABLE 83 GERMANY: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 106
TABLE 84 GERMANY: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 106
TABLE 85 GERMANY: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 107
TABLE 86 FRANCE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 107
TABLE 87 FRANCE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 108
TABLE 88 FRANCE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 108
TABLE 89 FRANCE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 109
TABLE 90 UK: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 109
TABLE 91 UK: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 110
TABLE 92 UK: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 110
TABLE 93 UK: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 111
TABLE 94 SPAIN: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 111
TABLE 95 SPAIN: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 112
TABLE 96 SPAIN: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 112
TABLE 97 SPAIN: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 113
TABLE 98 SWITZERLAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 113
TABLE 99 SWITZERLAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 114
TABLE 100 SWITZERLAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 114
TABLE 101 SWITZERLAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 115
TABLE 102 NETHERLANDS: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 115
TABLE 103 NETHERLANDS: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 116
TABLE 104 NETHERLANDS: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 116
TABLE 105 NETHERLANDS: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 117
TABLE 106 REST OF WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 117
TABLE 107 REST OF WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 118
TABLE 108 REST OF WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 118
TABLE 109 REST OF WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 119
TABLE 110 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 120
TABLE 111 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 121
TABLE 112 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 122
TABLE 113 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 122
TABLE 114 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 123
TABLE 115 DENMARK: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 123
TABLE 116 DENMARK: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 124
TABLE 117 DENMARK: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 124
TABLE 118 DENMARK: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 125
TABLE 119 SWEDEN: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 125
TABLE 120 SWEDEN: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 126
TABLE 121 SWEDEN: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 126
TABLE 122 SWEDEN: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 127
TABLE 123 NORWAY: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 127
TABLE 124 NORWAY: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 128
TABLE 125 NORWAY: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 128
TABLE 126 NORWAY: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 129
TABLE 127 ICELAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 129
TABLE 128 ICELAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 130
TABLE 129 ICELAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 130
TABLE 130 ICELAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 131
TABLE 131 FINLAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 131
TABLE 132 FINLAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 132
TABLE 133 FINLAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 132
TABLE 134 FINLAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 133
TABLE 135 IRELAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 133
TABLE 136 IRELAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 134
TABLE 137 IRELAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 134
TABLE 138 IRELAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 135
TABLE 139 REST OF NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 135
TABLE 140 REST OF NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 136
TABLE 141 REST OF NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 136
TABLE 142 REST OF NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 137
TABLE 143 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 138
TABLE 144 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 139
TABLE 145 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 140
TABLE 146 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 140
TABLE 147 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 141
TABLE 148 GREECE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 141
TABLE 149 GREECE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 142
TABLE 150 GREECE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 142
TABLE 151 GREECE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 143
TABLE 152 PORTUGAL: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 143
TABLE 153 PORTUGAL: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 144
TABLE 154 PORTUGAL: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 144
TABLE 155 PORTUGAL: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 145
TABLE 156 CROATIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 145
TABLE 157 CROATIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 146
TABLE 158 CROATIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 146
TABLE 159 CROATIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 147
TABLE 160 REST OF SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 147
TABLE 161 REST OF SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 148
TABLE 162 REST OF SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 148
TABLE 163 REST OF SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 149
TABLE 164 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 150
TABLE 165 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 151
TABLE 166 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 151
TABLE 167 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 152
TABLE 168 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 152
TABLE 169 HUNGARY: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 153
TABLE 170 HUNGARY: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 153
TABLE 171 HUNGARY: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 154
TABLE 172 HUNGARY: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 154
TABLE 173 SLOVAKIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 155
TABLE 174 SLOVAKIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 155
TABLE 175 SLOVAKIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 156
TABLE 176 SLOVAKIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 156
TABLE 177 CZECH REPUBLIC: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 157
TABLE 178 CZECH REPUBLIC: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 157
TABLE 179 CZECH REPUBLIC: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 158
TABLE 180 CZECH REPUBLIC: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 158
TABLE 181 AUSTRIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 159
TABLE 182 AUSTRIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 159
TABLE 183 AUSTRIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 160
TABLE 184 AUSTRIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 160
TABLE 185 REST OF CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 161
TABLE 186 REST OF CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 161
TABLE 187 REST OF CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 162
TABLE 188 REST OF CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 162
TABLE 189 AQUISITION 166
TABLE 190 FACILITY LAUNCH 168
TABLE 191 INVESTMENT 168
TABLE 192 EXPANSION 168
TABLE 193 KLIFO: SERVICES OFFERED 170
TABLE 194 KLIFO: KEY DEVELOPMENTS 171
TABLE 195 OPTIMAPHARM: SERVICES OFFERED 173
TABLE 196 OPTIMAPHARM: KEY DEVELOPMENTS 174
TABLE 197 FGK CLINICAL RESEARCH: SERVICES OFFERED 177
TABLE 198 FGK CLINICAL RESEARCH: KEY DEVELOPMENTS 178
TABLE 199 ERGOMED GROUP: SERVICES OFFERED 180
TABLE 200 ERGOMED GROUP: KEY DEVELOPMENTS 181
TABLE 201 ASTRUM/PHARMLOG: SERVICES OFFERED 184
TABLE 202 ASTRUM/PHARMLOG: SERVICES OFFERED 184
TABLE 203 KAPADI: SERVICES OFFERED 186
TABLE 204 TFS HEALTHSCIENCE: SERVICES OFFERED 189
TABLE 205 WINICKER NORIMED GMBH: SERVICES OFFERED 190
TABLE 206 JSB SOLUTIONS SRL: SERVICE OFFERED 193
TABLE 207 IQVIA HOLDING, INC: SERVICES OFFERED 195